George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.00
Bid: 51.00
Ask: 53.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.922%)
Open: 52.00
High: 52.00
Low: 52.00
Prev. Close: 52.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investor Webinar and Analyst Briefing

26 Apr 2023 07:00

RNS Number : 4481X
Cambridge Cognition Holdings PLC
26 April 2023
 

REACH

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Investor Webinar and Analyst Briefing

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, will be announcing the Company's preliminary financial results for the year ended 31 December 2022 on Wednesday 3 May 2023 and is pleased to provide details of an investor webinar and analyst briefing being held on that day.

Investor Webinar

Cambridge Cognition's management will be hosting an online presentation and Q&A session at 5.30 p.m. BST on Wednesday 3 May 2023. This session is open to all existing and prospective shareholders. Those wishing to attend should email cog@investor-focus.co.uk and they will be provided with log in details.

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: cog@investor-focus.co.uk .

Analyst Briefing

The Company's management will be hosting a presentation for analysts on the day of results at 9:30 a.m. BST, those who wish to attend the briefing should register their interest with Zach Cohen at zach.cohen@investor-focus.co.uk or on 020 3934 6637.

Enquiries

 

Cambridge Cognition Holdings Plc

Matthew Stork, Chief Executive Officer

Stephen Symonds, Chief Financial Officer

 

Tel: 012 2381 0700

press@camcog.com

Panmure Gordon (UK) Limited (NOMAD and Joint Broker)

Freddy Crossley / Emma Earl 

Rupert Dearden

 

Tel: 020 7886 2500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

 

Tel: 020 3903 7715

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

 cog@investor-focus.co.uk

 

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABIGDSRSDDGXU
Date   Source Headline
23rd Apr 20247:00 amRNSCOG spin-out Monument Therapeutics accesses £1.5m
2nd Apr 20244:20 pmRNSTotal Voting Rights and Block Listing Return
21st Mar 20247:00 amRNSFormation of new Scientific Advisory Board
21st Feb 202410:16 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSCambridge Cognition and ActiGraph Partnership
30th Jan 20244:20 pmRNSDirector/PDMR Share Purchases
30th Jan 20247:00 amRNSBoard appointments
30th Jan 20247:00 amRNSTrading Update
18th Dec 20237:00 amRNSGrant of Options
1st Dec 20237:00 amRNSTotal Voting Rights
22nd Nov 20237:00 amRNSChange of Auditor
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20237:00 amRNSAutomated quality assurance for clinical trials
11th Oct 20237:00 amRNSMajor contract win combining solutions
5th Oct 20235:33 pmRNSIssue of Warrants
3rd Oct 20232:43 pmRNSBlock listing Interim Review
28th Sep 20233:35 pmRNSHolding(s) in Company
26th Sep 20237:01 amRNSInterim Results
26th Sep 20237:00 amRNSSecured £3 million Term Loan
4th Sep 20237:00 amRNSNotice of Interim Results
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20234:26 pmRNSResult of AGM
13th Jun 20237:00 amRNS£2m contract for a pivotal cancer therapy trial
9th Jun 20237:00 amRNSNotice of AGM – Revision to Explanatory Note
6th Jun 20237:00 amRNSPosting of Annual Report & Notice of AGM
31st May 20237:00 amRNSCapital Markets Day
3rd May 20237:00 amRNSResults for the year ended 31 December 2022
26th Apr 20237:00 amRNSInvestor Webinar and Analyst Briefing
20th Apr 20237:00 amRNSNotice of Results
12th Apr 20237:00 amRNS£2.1 million contracts for rare disease trials
21st Mar 20237:00 amRNSBlock Admission Application & Exercise of Options
6th Feb 20237:00 amRNSDirector/PDMR Share Purchases
31st Jan 20237:00 amRNSTrading Update
30th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 202312:22 pmRNSHolding(s) in Company
17th Jan 20235:54 pmRNSHolding(s) in Company
17th Jan 20234:06 pmRNSHolding(s) in Company
13th Jan 20235:09 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSAcquisition of Winterlight Labs Inc
24th Nov 20227:00 amRNSStrategic Partnership for Chinese Market Expansion
19th Oct 20227:00 amRNS£1.1 million eCOA contract win
12th Oct 20227:00 amRNSAcquisition of eClinicalHealth Limited
20th Sep 20227:00 amRNSInterim Results
1st Sep 20227:00 amRNS£2.2m neurodegenerative disease trial contract
17th Aug 20227:00 amRNSAlzheimer’s Disease Validation for NeuroVocalix
3rd Aug 20222:55 pmRNSDirectorate Change
28th Jul 20227:00 amRNSPTSD trials with top 10 pharma company & US DoD
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.